Oramed Pharmaceuticals Inc (ORMP.OQ) Quote| Reuters.com
Edition:
United States

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

8.14USD
24 Jun 2016
Change (% chg)

$-0.01 (-0.12%)
Prev Close
$8.15
Open
$8.03
Day's High
$8.20
Day's Low
$7.86
Volume
15,916
Avg. Vol
23,162
52-wk High
$10.72
52-wk Low
$4.20

ORMP.OQ

Chart for ORMP.OQ

About

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible... (more)

Overall

Beta: 0.32
Market Cap(Mil.): $106.76
Shares Outstanding(Mil.): 13.12
Dividend: --
Yield (%): --

Financials

  ORMP.OQ Industry Sector
P/E (TTM): -- 38.82 34.11
EPS (TTM): -0.68 -- --
ROI: -26.70 -5.72 14.23
ROE: -28.73 -4.83 15.46

BRIEF-Oramed Pharmaceuticals unit enters into service agreement with XERTECS GmbH

* On June 13, 2016, Oramed Ltd entered into a service agreement with XERTECS GmbH

Jun 16 2016

BRIEF-Oramed announces positive top-line results from phase IIb oral insulin study

* Oramed announces positive top-line results from phase iib oral insulin study

May 18 2016

BRIEF-Oramed says to announce results from Phase 2B clinical trial in about 2 weeks

* Expects to announce results from its Phase 2B clinical trial for its ORMD-0801 oral insulin capsule in about two weeks time Source text for Eikon: [(http://1.usa.gov/1SNB87n )] Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 04 2016

BRIEF-Oramed Pharmaceuticals receives patent term adjustment extending the term of its U.S. patent

* Receives patent term adjustment extending the term of its U.S. patent

Apr 12 2016

BRIEF-Oramed Pharmaceuticals says patent granted in India

* Patent granted in India for oral administration of proteins Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Mar 29 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.